These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 23098112)

  • 21. Specific targeted therapy of chronic myelogenous leukemia with imatinib.
    Deininger MW; Druker BJ
    Pharmacol Rev; 2003 Sep; 55(3):401-23. PubMed ID: 12869662
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bosutinib.
    Keller G; Schafhausen P; Brümmendorf TH
    Recent Results Cancer Res; 2010; 184():119-27. PubMed ID: 20072835
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The European medicines agency review of bosutinib for the treatment of adult patients with chronic myelogenous leukemia: summary of the scientific assessment of the committee for medicinal products for human use.
    Hanaizi Z; Unkrig C; Enzmann H; Camarero J; Sancho-Lopez A; Salmonson T; Gisselbrecht C; Laane E; Pignatti F
    Oncologist; 2014 Apr; 19(4):421-5. PubMed ID: 24668331
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors.
    Kantarjian HM; Cortes JE; Kim DW; Khoury HJ; Brümmendorf TH; Porkka K; Martinelli G; Durrant S; Leip E; Kelly V; Turnbull K; Besson N; Gambacorti-Passerini C
    Blood; 2014 Feb; 123(9):1309-18. PubMed ID: 24345751
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New tyrosine kinase inhibitors in chronic myeloid leukemia.
    Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
    Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bosutinib for the treatment of chronic myeloid leukemia in chronic phase.
    Quintás-Cardama A; Kantarjian H; Cortes J
    Drugs Today (Barc); 2012 Mar; 48(3):177-88. PubMed ID: 22462037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib.
    Ernst T; Erben P; Müller MC; Paschka P; Schenk T; Hoffmann J; Kreil S; La Rosée P; Hehlmann R; Hochhaus A
    Haematologica; 2008 Feb; 93(2):186-92. PubMed ID: 18223278
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain.
    Levinson NM; Boxer SG
    PLoS One; 2012; 7(4):e29828. PubMed ID: 22493660
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tyrosine kinase inhibitors: the first decade.
    Agrawal M; Garg RJ; Cortes J; Quintás-Cardama A
    Curr Hematol Malig Rep; 2010 Apr; 5(2):70-80. PubMed ID: 20425399
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia.
    Weisberg E; Manley PW; Cowan-Jacob SW; Hochhaus A; Griffin JD
    Nat Rev Cancer; 2007 May; 7(5):345-56. PubMed ID: 17457302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].
    Usui N
    Rinsho Byori; 2004 Feb; 52(2):136-44. PubMed ID: 15027317
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glivec and CML: a lucky date.
    Saglio G; Cilloni D; Rancati F; Boano L
    J Biol Regul Homeost Agents; 2004; 18(2):246-51. PubMed ID: 15739279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
    Meggyesi N; Kozma A; Halm G; Nahajevszky S; Bátai A; Fekete S; Barta A; Ujj G; Lueff S; Sipos A; Adám E; Bors A; Reményi P; Masszi T; Tordai A; Andrikovics H
    Acta Haematol; 2012; 127(1):34-42. PubMed ID: 22005133
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia.
    Gambacorti-Passerini C; Cortes JE; Lipton JH; Dmoszynska A; Wong RS; Rossiev V; Pavlov D; Gogat Marchant K; Duvillié L; Khattry N; Kantarjian HM; Brümmendorf TH
    Am J Hematol; 2014 Oct; 89(10):947-53. PubMed ID: 24944159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resistance to targeted therapy in chronic myelogenous leukemia.
    Hochhaus A; Erben P; Ernst T; Mueller MC
    Semin Hematol; 2007 Jan; 44(1 Suppl 1):S15-24. PubMed ID: 17292737
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML.
    Valent P; Herndlhofer S; Schneeweiß M; Boidol B; Ringler A; Kubicek S; Gleixner KV; Hoermann G; Hadzijusufovic E; Müllauer L; Sperr WR; Superti-Furga G; Mannhalter C
    Oncotarget; 2017 Apr; 8(14):23061-23072. PubMed ID: 28416739
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of rifampin on the pharmacokinetics of bosutinib, a dual Src/Abl tyrosine kinase inhibitor, when administered concomitantly to healthy subjects.
    Abbas R; Boni J; Sonnichsen D
    Drug Metab Pers Ther; 2015 Mar; 30(1):57-63. PubMed ID: 25803093
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful treatment of follicular lymphoma with second-generation tyrosine kinase inhibitors administered for coexisting chronic myeloid leukemia.
    Fujiwara SI; Shirato Y; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Nagayama T; Mashima K; Umino K; Minakata D; Nakano H; Morita K; Yamasaki R; Kawasaki Y; Sugimoto M; Ashizawa M; Yamamoto C; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
    Int J Hematol; 2018 Jun; 107(6):712-715. PubMed ID: 29185155
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bosutinib - related pleural effusion in patients with chronic myeloid leukemia.
    Yüzbaşıoğlu MB; Eşkazan AE
    Expert Opin Drug Saf; 2021 Apr; 20(4):379-381. PubMed ID: 33339467
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.